Update on antiphospholipid syndrome

Bull NYU Hosp Jt Dis. 2008;66(3):195-7.

Abstract

This review addresses new clinical issues (revealed at the 2006 Sydney update of the 1999 Sapporo Classification criteria; cardiac, renal, and multiple sclerosis-like disease; catastrophic syndrome), mechanisms of action of antiphospholipid antibody (very likely complement mediated), current therapies (moderate dose warfarin recommended for prophylaxis, aspirin not recommended for primary prophylaxis), and potential new therapies.

Publication types

  • Review

MeSH terms

  • Antibodies, Antiphospholipid / blood
  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome* / blood
  • Antiphospholipid Syndrome* / complications
  • Antiphospholipid Syndrome* / drug therapy
  • Antiphospholipid Syndrome* / immunology
  • Aspirin / therapeutic use
  • Blood Coagulation
  • Complement System Proteins / metabolism
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use
  • Thrombosis* / blood
  • Thrombosis* / immunology
  • Thrombosis* / prevention & control
  • Warfarin / therapeutic use

Substances

  • Antibodies, Antiphospholipid
  • Anticoagulants
  • Platelet Aggregation Inhibitors
  • Warfarin
  • Complement System Proteins
  • Aspirin